Akoya Biosciences Inc

NASDAQ: AKYA    
Share price (5/17/24): $2.85    
Market cap (5/17/24): $141 million
Search in Documents
Key Exhibits
External Links
4 Akoya Biosciences Inc Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10.1
from 8-K 8 pages ​ Separation Agreement and Release ​
12/34/56
EX-10.1
from 8-K 7 pages ​ Separation Agreement and Release ​
12/34/56
EX-10.2
from 10-Q 5 pages ​ Tuesday, January 31, 2023
12/34/56
EX-10.1
from 10-Q 5 pages ​ Friday, January 27, 2023
12/34/56
EX-10.3
from 10-Q 5 pages We Are Very Pleased to Confirm Our Offer of Employment as Chief Medical Officer Reporting to Brian McKelligon, Chief Executive Officer. It Is Our Understanding That You Will Initially Be Working Remote From Oro Valley, Az Before Relocating to a Mutually Agreeable Location Near One of Our Sites. This Letter Confirms the Terms of Your Employment. ​ Compensation Akoya Biosciences, Inc. Shall Pay You a Salary of $450,000.00 Per Year Payable on a Semi- Monthly Pay Schedule, Subject to Applicable Tax Withholding Requirements. ​ Annual Bonus
12/34/56
EX-10.1
from 8-K 15 pages Akoya Biosciences, Inc. Executive Severance Plan and Summary Plan Description
12/34/56
EX-10.17
from 10-K 3 pages We Are Very Excited About the Prospects of Your Joining Akoya Biosciences, Inc. Should You Accept This Offer and Upon Successful Completion of a Pre-Employment Background Check and Drug Screen We Look Forward to Having You Join the Company in January 2022. This Letter Confirms the Terms of Your Employment. Position and Duties: You Shall Serve in the Position of Chief Human Resources Officer With Akoya Biosciences, Inc. (The “Company”) Reporting to Brian McKelligon, Chief Executive Officer
12/34/56
EX-10.16
from S-1/A 9 pages March 2, 2021 Position and Duties: You Shall Serve in the Position of Chief Operating Officer With Akoya Biosciences, Inc. (The “Company”) Reporting to Brian McKelligon, CEO
12/34/56
EX-10.3
from S-1/A 23 pages Akoya Biosciences, Inc. 2021 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 44 pages Akoya Biosciences, Inc. 2021 Equity Incentive Plan
12/34/56
EX-10.16
from S-1 5 pages March 2, 2021 Position and Duties: You Shall Serve in the Position of Chief Operating Officer With Akoya Biosciences, Inc. (The “Company”) Reporting to Brian McKelligon, CEO
12/34/56
EX-10.15
from S-1 44 pages Amended and Restated Investors’ Rights Agreement
12/34/56
EX-10.13
from S-1 25 pages Exclusive Patent License Agreement
12/34/56
EX-10.12
from S-1 28 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed Transition Services Agreement
12/34/56
EX-10.11
from S-1 26 pages Agreement
12/34/56
EX-10.10
from S-1 5 pages Amendment No 1 to the License Agreement Effective the 17th Day of November 2015 Between Stanford University and Akoya Biosciences
12/34/56
EX-10.9
from S-1 29 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed
12/34/56
EX-10.8
from S-1 3 pages July 14, 2020 Position and Duties: Compensation
12/34/56
EX-10.7
from S-1 3 pages January 28, 2019 Compensation
12/34/56
EX-10.6
from S-1 2 pages Confidential October 8, 2018
12/34/56